In breast cancer, simvastatin inhibits HMGCR expression and suppresses the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4) production, which induces cancer cell ferroptosis [10]. Here, GPX4 is linked to breast carcinoma.